News
We previously covered Comcast (NASDAQ:CMCSA) in July 2023, discussing its excellent prospects through the year, thanks to the Mario movie’s blockbuster performance, further aided...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Yiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked...
News
This article was written by Follow Samuel Smith has a diverse background that includes being lead analyst and Vice President at several highly regarded...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
A couple of years ago, I had a late-night hankering for some fast food, so I stopped by my local establishment. I generally avoided...
News
Investment thesis From the secular point of view, I am a big fan of the U.S. stock market because it has a stellar growth...
News
Millions of student loan borrowers have to make a payment this month for the first time in over three years. The moratorium on student...
News
Enphase Energy, Inc. (NASDAQ:ENPH) is down 61% year-to-date to maintain a drawdown that has seen the poster boy of the solar revolution shed around...
News
Company Description Academy Sports and Outdoors (NASDAQ:ASO) – Consumer Discretionary – Specialty retailer Founded in 1938, Academy Sports And Outdoors (“the company”) is a...
News
SolarEdge Technologies (NASDAQ:SEDG) has been a very strong performer since its public offering at $18 per share in 2015, but it has run into...
News
Introduction A new wave of covered call ETFs have swept unsuspecting income investors away with eye-popping distribution rates. The YieldMax TSLA Option Income Strategy...
News
Welcome to another installment of our CEF Market Weekly Review, where we discuss closed-end fund (“CEF”) market activity from both the bottom-up – highlighting...
News
At a Glance United Therapeutics’ (NASDAQ:UTHR) Q2 performance underscores robust financials with a notable 27.7% YoY revenue increase, fueling investor optimism. On the clinical...
